Moolec Science SA filings document a foreign private issuer developing molecular farming and precision fermentation technologies for food-ingredient applications. Its Form 6-K reports and annual materials cover shareholder meeting matters, consolidated financial statements, board composition, Nasdaq continued-listing compliance, share consolidation, and incorporation of certain reports into its Form S-8 registration statement.
The filing record also documents capital-structure and control matters, including preference-share conversion and the emergence of a controlling shareholder, as well as accounting disclosures related to loss of control and derecognition of subsidiaries following bankruptcy proceedings. These disclosures frame the company’s governance, ownership, reporting status, and public-company obligations alongside its operating business.
Moolec Science SA reported the results of its virtual annual general meeting of shareholders held on May 13, 2026. Shareholders representing 1,482,096 ordinary shares out of 2,080,437 entitled to vote, or 71.240%, were present, satisfying quorum requirements.
Investors approved the consolidated financial statements for the financial year ended June 30, 2025. They also re-elected directors Diego Abelleyra Llodra, Oscar Leon Bentancor, Romualdo Varela, and Daniel Core for terms lasting until the next annual general meeting or until successors are appointed.
Shareholders further approved the re-appointment of Price Waterhouse & Co. S.R.L. as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026. All three resolutions passed as ordinary resolutions by more than a simple majority of votes cast.
Moolec Science reports unaudited interim results for the six months ended December 31, 2025. The Group posted a profit of US$92.0 million, reversing a prior-period loss of US$36.8 million, mainly due to a US$129.3 million gain from deconsolidating distressed subsidiaries classified as discontinued operations.
Continuing operations remain small and loss-making, with revenue of US$5.2 million, an operating loss of US$6.2 million and a loss from continuing operations of US$10.3 million. Shareholders’ equity swung from a deficit of US$(84.5) million to positive US$15.2 million, helped by deconsolidation and conversion of preference shares.
The company discloses a material uncertainty about its ability to continue as a going concern, citing negative working capital, loss of access to prior financing structures and reliance on new funding. A major shareholder’s subsidiary has provided a credit line of up to US$6 million, but management indicates that further financings and cost actions are needed.
Moolec Science reports that it has regained compliance with all Nasdaq Capital Market continued listing requirements related to the minimum stockholders’ equity standard within the remediation period granted by the Nasdaq Hearings Panel. The company reported stockholders’ equity of approximately $15.2 million as of March 31, 2026 and $11.3 million as of December 31, 2025.
An equity-strengthening step was the partial conversion of preference shares, with ordinary shares valued at $5,473,425 recorded as equity as of December 31, 2025. Moolec’s preliminary March 31, 2026 balance sheet shows total assets around $104 million, including $71.6 million of intangible assets and $16.0 million in investments in joint ventures and associates, alongside borrowings and convertible notes totaling over $70 million.
The company also reflects a pro forma adjustment for $465,161 drawn under a related-party credit line in April 2026 and states that it expects to request conversion of the remaining $4.0 million of preference shares within the next 12 months, which it indicates is expected to further strengthen stockholders’ equity.
Moolec Science filed a Form 6-K to share the notice of its virtual Annual General Meeting of shareholders. The AGM will be held on May 13, 2026 at 9:00 a.m. Eastern Time.
Shareholders will vote on three proposals: approval of the consolidated financial statements for the year ended June 30, 2025, re-election of four directors (Daniel Core, Diego Abelleyra Llodra, Oscar Leon Bentancor and Romualdo Varela), and re-appointment of Price Waterhouse & Co. S.R.L. as independent registered public accounting firm for the fiscal year ending June 30, 2026.
Holders of shares as of the April 6, 2026 record date are eligible to vote, primarily by submitting proxies by May 11, 2026 at 11:59 p.m. Eastern time. The meeting will be conducted virtually via a dedicated hosting page with telephone listen-only access.
Moolec Science SA director Daniel Joaquin Core filed a Form 3 reporting existing equity awards rather than any new share purchases or sales. He reports direct holdings of options over 934 ordinary shares at an exercise price of $7.14 expiring on June 30, 2031, plus separate option holdings over 933 shares expiring on June 30, 2032 and another 933 shares expiring on June 30, 2033.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.